Biosense Webster, Inc.

Clinical trials sponsored by Biosense Webster, Inc., explained in plain language.

Now part of Johnson & Johnson JNJ NYSE

A medical device company specializing in cardiac electrophysiology and catheter-based treatments.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New heart mapping catheter put to the test Results expected Sep 2026 (estimated)
New heart tool aims to simplify AFib treatment Results expected Dec 2026 (estimated)
New heart tool aims to make AFib treatment faster and safer Results expected Dec 2026 (estimated)
New catheter combo aims to keep AFib in check longer Results expected Dec 2026 (estimated)
New heart procedure aims to zap away atrial fibrillation safely Results expected Jul 2027 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 8 Not yet recruiting 1 Not yet finished but already full! 4 Completed 6

Can an unapproved device tame disease? a trial puts it to the test

Disease control Not yet recruiting

Researchers are testing a medical device that has not been approved or cleared by the U.S. FDA. The trial aims to see whether the device can help control a disease, possibly by reducing symptoms or slowing its course. Participants receive the device as part of the study, and the …

Sponsor: Biosense Webster, Inc. • Aim: Disease control

Last updated Sep 17, 2026 00:00 UTC

Biosense Webster, Inc.

Upcoming readouts

Can an unapproved device tame disease? a trial puts it to the test